证券代码：300451 证券简称：创业慧康 公告编号：2026-006 创业慧康科技股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2026 年 3 月 6 日，创业慧康科技股份有限公司（以下简称"公司"）收到 股东杭州更好智投管理咨询合伙企业（有限合伙）（以下简称"杭州更好"）出 具的《关于5%以上股东股份质押的告知函》，获悉杭州更好将所持股份43,436,294 股质押给兴业银行股份有限公司上海南汇支行（以下简称"兴业银行"），双方 于 2026 年 3 月 4 日办理完毕质押登记手续。现将具体内容公告如下： | 股东 名称 | 是否为 第一大 股东及 | 本次质押股 数（股） | 占其所持 股份比例 | 占公司总 股份比例 | 是否 为限 | 是否 为补 充质 | 质押起始 日 | 质押到 期日 | 质权 人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行 动人 | | | | 售股 | 押 | ...

每经AI快讯，有投资者在投资者互动平台提问：飞利浦系董事辞职，股票减持，对双方合作有影响 吗？飞跃康后续还会继续开发吗？ （文章来源：每日经济新闻） 创业慧康（300451.SZ）2月27日在投资者互动平台表示，公司董事谢寜炜女士因个人工作原因，申请辞 去公司非独立董事职务。飞利浦（中国）投资有限公司与飞利浦医疗器械（上海）有限公司之间的股权 转让，属于同一控制人下不同主体之间的内部转让目前公司与飞利浦一直正常保持业务合作。请注意投 资风险！ ...

创业慧康（300451.SZ）2月27日在投资者互动平台表示，公司与华检医疗在客户群体与决策链上高度重 合，双方协同以资源共享与路径复用为重点，将有效提升运营效率。协同合作不仅限于市场前端，未来 将通过业务贯通、数智决策、流通赋能的三级释放路径，打破数据壁垒，为医疗卫生机构提供更高效、 精准、可持续的医疗解决方案。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：董秘您好，华检医疗成为公司控股股东后，双方在医 疗信息化与体外诊断（IVD）领域的协同战略具体如何规划？新股东将在哪些方面为公司导入资源、资 金或客户，以帮助公司扭转当前的亏损局面？ ...

Core Insights - The report from Zhonghang Securities highlights the ongoing integration of AI products and services in the healthcare sector, focusing on areas such as medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics. AI is evolving from a "technical assistant" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the medical industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] International Developments - In the international arena, significant advancements are noted in AI medical imaging diagnostics and AI-assisted drug discovery. AI systems for abdominal CT multi-disease triage and fetal abnormal ultrasound imaging have received FDA approval, indicating a shift from single-disease assistance to comprehensive triage and decision support systems. Collaborations between pharmaceutical companies and AI tech firms are enhancing cancer early screening capabilities, potentially increasing cancer diagnosis rates and accessibility to treatment drugs. Additionally, AI imaging diagnostics for stroke have gained recognition at top academic conferences, reflecting the growing acceptance of AI technology in clinical and research communities [1] - In drug discovery, international pharmaceutical companies are partnering with AI tech firms to accelerate new drug development. The world's first fully AI-designed antibody drug, GB-0895, has entered Phase III clinical trials, marking a significant breakthrough from concept to clinical practice. Google has also launched two open-source AI models for medical applications, enhancing capabilities in multi-modal analysis and voice interaction [1] Domestic Developments - Domestically, the value of AI in early drug development is being clinically validated, with companies like InSilico Medicine receiving FDA approval for new drug applications via AI platforms. AI-assisted diagnosis is expanding into various medical scenarios, with recent approvals for AI software in cervical cell digital pathology and accelerated AI healthcare initiatives from leading in vitro diagnostic companies. The emergence of large AI models in China is also noteworthy, with local teams publishing evaluation standards in international journals, showcasing the competitive edge of Chinese medical AI models [2] - Significant advancements are being made in AI imaging, surgical robots, and brain-computer interfaces, with AI accelerating the development of medicine and drug research. Recent policies related to AI in healthcare are being actively discussed, focusing on the reliability and compliance of AI-assisted diagnosis and the use of medical data [2] Investment Opportunities - Key investment opportunities identified include: 1) AI drug development: companies like Crystal Technology, Hongbo Pharmaceutical, Chengdu XianDao, and InSilico Medicine 2) AI medical imaging and assisted diagnosis: companies such as United Imaging Healthcare and Wandong Medical 3) Medical information technology and smart hospitals: firms like Jiahe Meikang, Chuangye Huikang, Donghua Software, and Weining Health 4) Internet healthcare and health platforms: including JD Health, Alibaba Health, and Ping An Good Doctor 5) Precision medicine and AI-driven medical services: companies like Kingmed Diagnostics, Runda Medical, and Meinian Health 6) Technology/data platform enterprises: such as iFlytek Medical and Yidu Technology [4] AI Medical Core Themes - The core themes in AI healthcare investment revolve around addressing industry pain points. AI-assisted diagnosis enhances diagnostic efficiency and consistency, supporting grassroots healthcare with clear cost-reduction and efficiency benefits. In cancer early screening, companion diagnostics, and efficacy prediction, AI contributes to achieving precision medicine. The maturity of AI applications varies, with AI medical imaging evolving from single-disease assistance to multi-disease integration and comprehensive management. AI-assisted drug discovery is transitioning from early discovery to clinical validation, necessitating attention to platform technology validation and deep collaborations with top pharmaceutical companies [3] - The development of large medical AI models and multi-modal AI, capable of processing diverse medical data, is crucial. The focus should be on the accuracy of these models in specialized fields, their integration with existing hospital information systems, and their potential to build an ecosystem as foundational "medical intelligent agents" [3]

格隆汇2月24日丨创业慧康(300451.SZ)在互动平台表示，公司暂无探索太空互联网医院的计划。 ...

证券日报网讯 2月12日，创业慧康发布公告称，控股股东葛航于2026年2月9日至10日分笔解除质押合计 120814266股，占其原持股77.55%，对应质权人国元证券、巢湖新投、杭州更好均已办理登记，解押后 葛航仍质押2200万股，占其现持股37.13%。 （编辑 丛可心） ...

每经AI快讯，创业慧康2月12日晚间发布公告称，2月11日，公司收到股东葛航先生的《告知函》，获 悉葛航先生将其持有的本公司部分股票办理解除质押登记手续，解除质押共计约1.21亿股股票。截至本 公告日，葛航累计质押股数为2200万股，合计占其所持股份比例为37.13%。 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 （记者 王晓波） ...

Core Viewpoint - The announcement reveals that shareholder Ge Hang has released a total of 121 million shares from pledge, indicating a significant change in the ownership structure and potential liquidity for the company [1] Group 1: Shareholder Actions - Ge Hang has released 121 million shares from pledge, which includes 65.03 million shares pledged to Guoyuan Securities, 28.78 million shares to Chaohu Xintou, and 27.03 million shares to Hangzhou Genghao [1] - The released shares account for 77.55% of Ge Hang's original holdings and 7.80% of the company's total share capital [1] - After the release, Ge Hang still has 22 million shares pledged, which represents 37.13% of his current holdings and 1.42% of the company's total share capital [1]

证券代码：300451 证券简称：创业慧康 公告编号：2026-005 创业慧康科技股份有限公司 关于股东部分股份解除质押的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2026 年 2 月 11 日，创业慧康科技股份有限公司（以下简称"公司"）收到 股东葛航先生的《告知函》，获悉葛航先生将其持有的本公司部分股票办理解除 质押登记手续，具体包括：质押给国元证券股份有限公司（以下简称"国元证券"） （65,002,800 股）、巢湖新投房地产开发有限公司（以下简称"巢湖新投"） （28,777,331 股）、杭州更好智投管理咨询合伙企业（有限合伙）（以下简称"杭 州更好"）（27,034,135 股），共计 120,814,266 股股票，前述质权人均已办理 解除质押登记手续。现将具体内容公告如下： 注：上表中解除质押股数占其所持股份的比例为基于葛航先生协议转让过户 完成前的所持总股数（155,780,282 股）计算。 二、股东股份累计质押的情况 | | | | | | 累计 | | 合计 | 已质押股份 | | 未质押股份 | | | --- | --- ...

证券代码：300451 证券简称：创业慧康 公告编号：2026-004 创业慧康科技股份有限公司 关于筹划控制权变更事项进展暨协议转让股份完成过户 登记的公告 行事项（"向特定对象发行股票"）。此外，杭州更好拟向公司提名四名非独立 董事、两名独立董事人选（"董事会改选"）。无论公司是否完成向特定对象发 行股票事项，若杭州更好提名的上述董事全部当选且占公司董事会席位的半数以 上，将导致公司控制权变更，杭州更好成为公司的控股股东。 3、根据中国证券登记结算有限责任公司出具的《证券过户登记确认书》，本 次协议转让所涉及的股份已于 2026 年 2 月 11 日办理完成了过户登记手续。杭州 更好拥有公司股份 96,525,096 股，占公司总股本的 6.23%。 4、公司股东筹划控制权变更事项仍在进行中，董事会改选、向特定对象发行 股票等事项能否最终实施完成及实施结果尚存在不确定性。公司将持续关注后续 进展情况，并督促相关股东及时履行信息披露义务，敬请广大投资者理性投资， 注意投资风险。 一、协议转让概述 2025 年 11 月 12 日，杭州更好与葛航先生签署《股份转让协议》，受让葛 航先生持有的公司 96,525 ...